CJC-1295

Mechanism of Action

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), the 44-amino-acid hypothalamic neuropeptide that drives pulsatile growth hormone (GH) secretion from the anterior pituitary. The native GHRH molecule is subject to rapid inactivation by dipeptidyl peptidase IV (DPP-IV), which cleaves between positions 2 and 3, and by non-specific plasma peptidases, resulting in a plasma half-life of 7–10 minutes for the endogenous hormone. CJC-1295 was developed by ConjuChem Biotechnologies to address this pharmacokinetic liability through two distinct strategies, yielding two related but pharmacologically distinct compounds that are frequently conflated in research and community discussions.

The shorter, biologically active core of GHRH is encompassed within the first 29 amino acids (GHRH[1-29]), which retains full receptor-binding and GH-releasing activity. Modified GRF(1-29) — also called CJC-1295 without DAC, or Mod GRF 1-29 — incorporates four amino acid substitutions relative to native GHRH[1-29]: Ala at position 2 is replaced by D-Ala (conferring DPP-IV resistance), Phe at position 27 is replaced by Norvaline, Arg at position 29 is added with Amidation at the C-terminus, and Gln at position 8 is replaced by Ala. These substitutions substantially increase resistance to enzymatic degradation, extending plasma half-life to approximately 30 minutes compared to roughly 7 minutes for unmodified GHRH[1-29].

CJC-1295 with DAC (Drug Affinity Complex) — the compound most commonly referred to simply as "CJC-1295" in clinical trial literature — adds a further modification: a reactive maleimide group (the DAC moiety) at the C-terminus that covalently binds to the lysine-38 residue of circulating albumin shortly after injection. Because albumin has a plasma half-life of approximately 19 days in humans, this covalent coupling dramatically extends the effective half-life of CJC-1295 to approximately 6–8 days. This transforms the compound from a short-acting pulsatile GH secretagogue to a sustained-release GHRH analogue capable of maintaining elevated GH and IGF-1 for over a week from a single injection.

Both variants act at the same molecular target: the GHRH receptor (GHRHR), a class B G-protein coupled receptor expressed on somatotroph cells of the anterior pituitary. GHRHR couples to Gαs, activating adenylyl cyclase, elevating intracellular cAMP, and activating protein kinase A (PKA). PKA phosphorylates cAMP response element-binding protein (CREB), which drives transcription of the GH gene (GH1) and promotes GH secretion from stored granules. Sustained GHRHR activation also promotes somatotroph cell proliferation and maintenance of GH synthetic capacity over time.

The GH released by CJC-1295 stimulation acts on GH receptors (GHR) in the liver and peripheral tissues, driving expression of insulin-like growth factor 1 (IGF-1, encoded by IGF1). Hepatic IGF-1 constitutes the majority of circulating IGF-1 and mediates many of GH's anabolic effects on muscle, bone, and connective tissue via the IGF-1 receptor (IGF1R), which signals through the PI3K-Akt-mTOR and Ras-MAPK pathways. GH also exerts direct effects on adipose tissue (lipolysis via hormone-sensitive lipase), bone (osteoblast stimulation), and metabolism (partial insulin antagonism).

An important physiological consideration is the GH pulse architecture. The DAC form of CJC-1295, by providing sustained GHRHR stimulation, blunts the natural pulsatile pattern of GH secretion and instead produces a chronic baseline GH elevation. This contrasts with the non-DAC form, which, when timed appropriately relative to natural GH pulses, augments individual pulses while preserving pulsatile dynamics. Whether chronic non-pulsatile GH elevation — as produced by the DAC version — has equivalent biological effects to augmented pulsatile GH release remains an open question with implications for efficacy and long-term safety.

Compared to sermorelin, an earlier 29-amino-acid GHRH analogue used clinically for GH deficiency diagnosis and treatment, CJC-1295 offers substantially greater DPP-IV resistance and, in its DAC form, the albumin-binding extension. Sermorelin (GHRH[1-29]) has a half-life of approximately 11 minutes and requires multiple daily injections for sustained GH elevation, limiting practical utility.

Pharmacokinetics

The pharmacokinetics of CJC-1295 with DAC have been formally characterized in Phase I clinical trials. Following a single SubQ injection in healthy adults, the compound demonstrates dose-dependent increases in mean plasma GH concentrations with a time-to-peak of approximately 2–6 hours and a sustained elevation lasting 6–9 days. The albumin-bound fraction behaves kinetically as an albumin pool depot, slowly releasing free peptide. Terminal half-life has been reported at approximately 5.8–8.1 days across dose cohorts in the published Phase I data.

IGF-1 elevation parallels and slightly lags the GH curve, consistent with hepatic synthesis dynamics. In the published Phase I trial (Teichman et al., J Clin Endocrinol Metab, 2006), mean IGF-1 concentrations increased approximately 1.5–3-fold above baseline and remained elevated for up to 28 days at higher doses, reflecting the slow kinetics of IGF-1 turnover relative to GH.

CJC-1295 without DAC (Mod GRF 1-29) has not been characterized in the same formal clinical setting, but its pharmacokinetics are inferred from its structural properties: DPP-IV resistance extends plasma half-life to approximately 30 minutes, producing a GH pulse that rises over 15–30 minutes post-injection and returns toward baseline within 2–4 hours. This profile is suited to pulse-timing strategies where injection is timed to coincide with naturally low somatostatin tone (typically at sleep onset or in the fasting state).

Subcutaneous bioavailability for peptides of this size and charge profile is generally good, though formal bioavailability data for CJC-1295 relative to IV administration has not been published. Distribution is primarily vascular and interstitial for the albumin-bound form. CNS penetration is not expected at pharmacologically significant concentrations.

Degradation occurs primarily through proteolytic cleavage by circulating and tissue proteases, with eventual renal clearance of small peptide fragments and constituent amino acids. The albumin-bound form is additionally subject to lysosomal degradation following endocytosis of the albumin conjugate.

No significant hepatic cytochrome P450 metabolism is expected given the peptide nature of the compound.

Reported Effects

Primary Research Findings

• GH and IGF-1 elevation (human, Phase I): Teichman et al. (J Clin Endocrinol Metab, 2006) — single-dose study in 64 healthy volunteers aged 21–61. CJC-1295 with DAC at 30–120 µg/kg SubQ produced mean GH increases of 2–10-fold over baseline, with sustained elevation over 6 days. IGF-1 increased 1.5–3-fold and remained elevated for up to 28 days at the highest doses. The dose-response relationship was characterised as broadly linear within the studied range.
• Tolerability in Phase I: The same study reported that the compound was generally well-tolerated at all doses. Injection site reactions, flushing, and headache were the most commonly noted adverse events.
• Body composition (pre-clinical): Rodent studies report increased lean body mass and reduced adiposity with sustained CJC-1295 with DAC administration, consistent with the known anabolic and lipolytic effects of GH/IGF-1 elevation. Specific effect magnitudes vary across models.
• Bone density (pre-clinical): GH-axis activation in rodent models of GH deficiency and aging results in improvements in bone mineral density, consistent with known GH/IGF-1 effects on osteoblast function.
• GH pulse augmentation (non-DAC form): Short-acting GHRH analogues including Mod GRF 1-29 augment GH pulse amplitude when administered at appropriate time points. Human data from sermorelin studies (the closest pharmacologically characterized analogue) demonstrate that repeated SubQ dosing at night increases mean overnight GH secretion and IGF-1.

Secondary / Emerging Findings

• Sleep quality: Increased GH secretion during slow-wave sleep is physiologically normal, and GH secretagogues are widely reported to subjectively improve sleep depth in self-experimental contexts. Controlled sleep architecture studies with CJC-1295 specifically have not been published.
• Wound healing and connective tissue: IGF-1 is a known driver of collagen synthesis in fibroblasts and tenocytes. By inference, CJC-1295-driven IGF-1 elevation may support connective tissue repair, but this has not been studied directly with CJC-1295 in controlled trials.
• Cognitive function: GH and IGF-1 have documented effects on hippocampal neurogenesis and synaptic plasticity. Whether CJC-1295-level GH/IGF-1 elevation produces meaningful cognitive benefits in healthy adults has not been studied.
• Immune modulation: GH receptors are expressed on immune cells, and GH is known to have immunomodulatory properties. Community reports of improved immune resilience are consistent with this biology but have not been formally studied.

Effects Not Yet Demonstrated in Humans

Phase I data addresses pharmacokinetics and acute tolerability. No Phase II or III trials examining body composition, recovery, athletic performance, aging-related outcomes, cognitive function, or any clinical endpoint have been completed and published for CJC-1295 with DAC. The non-DAC form (Mod GRF 1-29) has not been studied in formal human trials to the authors' knowledge.

Body composition and performance claims frequently circulated in research communities are not supported by controlled human data. While the GH/IGF-1 axis effects are mechanistically plausible, magnitude, durability, and safety at doses used in practice remain uncharacterized.

Dosing & Administration

CJC-1295 with DAC — published clinical dosing: The Phase I trial used doses of 30, 60, 90, and 120 µg/kg as single SubQ injections. In a 75 kg individual, this corresponds to roughly 2.25 mg, 4.5 mg, 6.75 mg, and 9 mg respectively. These doses are substantially higher than those typically described in community use.

CJC-1295 with DAC — community practice: Doses of 1–2 mg once or twice weekly are most commonly described in self-experimental contexts. This represents a lower dose relative to the Phase I study but produces measurable GH and IGF-1 elevation based on the pharmacokinetic data.

CJC-1295 without DAC (Mod GRF 1-29) — community practice: Doses of 100 µg administered 2–3 times daily are most commonly described. Injections are typically timed to coincide with GH troughs — most commonly pre-sleep and pre-training in the fasting state — to maximize pulse amplitude without somatostatin interference. No formal human dosing studies for this form exist.

Combination with GHRPs (particularly Ipamorelin): CJC-1295 (either form) is commonly combined with ipamorelin or other growth hormone-releasing peptides (GHRPs) in research settings. GHRH receptor agonism and GHS-R1a agonism act through distinct, synergistic mechanisms on somatotroph cells, and the combination of a GHRH analogue plus a GHRP produces substantially greater GH secretion than either agent alone — an effect that has been characterized in pre-clinical models and inferred from human analogue data. The interaction is mechanistically well-supported.

Compounding and purity considerations: CJC-1295 is available from research peptide suppliers of variable quality. The DAC form in particular can be challenging to synthesize with the reactive maleimide group intact. Third-party mass spectrometry verification is recommended for research applications.

Side Effects & Safety Profile

Commonly Observed

In the Phase I clinical trial, the most frequently reported adverse events were injection site reactions (pain, erythema, swelling), flushing, headache, and dizziness. These were predominantly mild, transient, and resolved without treatment. Water retention, consistent with GH's anti-natriuretic effects, has been reported at higher doses.

Less Common

Joint stiffness and carpal tunnel-like symptoms (paraesthesias in the hands consistent with median nerve compression from fluid accumulation) have been reported and are consistent with known GH side effects. Mild increases in fasting blood glucose may occur due to GH's insulin-antagonistic effects on glucose metabolism. Elevated fatigue and lethargy immediately post-injection, likely related to the acute GH surge, have been noted.

Contraindications & Warnings

IGF-1 supraphysiological elevation: The most important safety consideration with sustained CJC-1295 DAC use is the risk of elevating IGF-1 beyond the physiological range. Chronic supraphysiological IGF-1 has been associated in epidemiological studies with increased risk of prostate, colorectal, and premenopausal breast cancer. While the effect sizes in observational data are modest and confounded, this remains a meaningful biological concern.

Acromegaly risk: Exogenous GH axis stimulation over extended periods carries theoretical risk of contributing to acromegalic features (coarsened facial features, soft tissue overgrowth, organomegaly, joint pathology). This risk is relevant primarily at sustained high doses.

Pituitary axis suppression: Prolonged non-pulsatile GHRHR stimulation, as produced by the DAC form, may progressively reduce pituitary responsiveness through GHRHR downregulation. The duration and dose threshold at which clinically meaningful desensitization occurs in humans has not been established.

Pre-existing malignancy: GH and IGF-1 are mitogenic signals. Use in individuals with active or prior hormone-sensitive cancers is contraindicated based on mechanistic grounds.

Diabetes and insulin resistance: GH elevation reduces insulin sensitivity. Individuals with type 2 diabetes, pre-diabetes, or metabolic syndrome should exercise particular caution.

Long-term human safety: The Phase I trial characterized acute and short-term tolerability. Long-term safety data extending beyond weeks to months of use in humans does not exist in the published literature.

Clinical Evidence

The primary clinical evidence base for CJC-1295 consists of a single published Phase I trial:

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." J Clin Endocrinol Metab. 2006;91(3):799-805.

This randomized, double-blind, placebo-controlled Phase I/II trial enrolled 64 healthy adults (21–61 years) and examined single and multiple doses of CJC-1295 with DAC. Key findings: dose-dependent, sustained GH and IGF-1 elevation; mean GH AUC increases of 2–10-fold; IGF-1 elevation persisting up to 28 days at highest doses; generally good tolerability with mild adverse events.

ConjuChem Biotechnologies, the developer, did not advance CJC-1295 to Phase III trials, and the compound's clinical development was discontinued. This leaves the Phase I data as the complete extent of human clinical evidence.

Evidence grade: B — Single Phase I human trial with clear pharmacokinetic and pharmacodynamic characterization; no efficacy data from controlled human trials on clinical endpoints (body composition, performance, aging); no Phase III data; well-characterized mechanism based on established GHRH receptor pharmacology.

Comparison with sermorelin — a structurally related GHRH[1-29] analogue that achieved FDA approval for GH deficiency — is instructive for understanding the mechanistic plausibility of CJC-1295's effects, though sermorelin's clinical development pathway involved more extensive controlled trial data than exists for CJC-1295.

Interaction Considerations

Somatostatin analogues (octreotide, lanreotide): These directly oppose GHRHR signaling by inhibiting GH release via somatostatin receptor (SSTR) activation. Concomitant use would be expected to significantly attenuate CJC-1295's GH-releasing effects. This combination would not typically arise in research practice but is clinically relevant for individuals prescribed somatostatin analogues for acromegaly or neuroendocrine tumors.

GHRPs (Ipamorelin, GHRP-2, GHRP-6, hexarelin): Synergistic combination — GHRH receptor and GHS-R1a activation produce additive to synergistic GH release. The CJC-1295 / Ipamorelin combination is the most widely studied in community practice and has mechanistic support from published studies on GHRH + GHRP combinations in animal and human models.

Insulin: GH's insulin-antagonistic effects may require insulin dose adjustments in diabetic individuals. Concomitant GH axis activation and exogenous insulin use may introduce unpredictable glucose dynamics.

Glucocorticoids: Chronic glucocorticoid use suppresses GH secretion and reduces pituitary GHRHR expression. CJC-1295 may have reduced efficacy in individuals on systemic corticosteroids.

Thyroid hormone: Hypothyroidism reduces GH axis activity; thyroid hormone replacement optimizes the environment for GH secretion and may be a relevant consideration in subclinical hypothyroid individuals.

IGF-1 and rhIGF-1 analogues: Concomitant use would compound IGF-1 elevation and increase the risk of hypoglycemia and IGF-1-related adverse effects.

Discovery & Research Timeline

• Late 1990s: ConjuChem Biotechnologies (Montreal, Canada) develops the Drug Affinity Complex (DAC) technology platform, applying reactive bioconjugation chemistry to extend peptide half-life via in vivo albumin binding. GHRH is selected as a target for application of this platform.
• 2001–2003: CJC-1295 with DAC is synthesized, characterized, and advanced through pre-clinical pharmacology studies. The albumin-binding kinetics and GH-releasing properties in rodent and non-human primate models are established.
• 2004–2005: Phase I clinical trial initiates in healthy volunteers. Single-dose and multiple-dose arms examine pharmacokinetics, pharmacodynamics (GH and IGF-1 profiles), and safety.
• 2006: Teichman et al. publish Phase I results in Journal of Clinical Endocrinology and Metabolism, establishing 5.8–8.1 day half-life with DAC, dose-dependent GH/IGF-1 elevation, and a generally acceptable acute safety profile.
• 2007–2010: ConjuChem advances CJC-1295 toward Phase II. However, the company encounters financial difficulties and ultimately does not complete Phase II trials. Formal clinical development is discontinued.
• 2008–2012: The compound enters research peptide markets. Distinction between CJC-1295 with and without DAC becomes a source of widespread confusion in community forums. Mod GRF 1-29 (without DAC) is separately synthesized and distributed under the "CJC-1295 no DAC" label by various suppliers.
• 2010s: The CJC-1295 / Ipamorelin combination emerges as one of the most widely discussed GHRH + GHRP combinations in research communities. No additional human clinical data is generated.
• 2020–present: CJC-1295 remains one of the most commonly researched GH-axis peptides despite absence of clinical efficacy trials. Regulatory scrutiny of the research peptide market intensifies in the United States, with FDA enforcement actions against suppliers increasing.

Research Disclaimer

CJC-1295 has not been approved by the FDA, EMA, or any equivalent regulatory body for any therapeutic indication. While Phase I pharmacokinetic and tolerability data exists in healthy human volunteers, no controlled efficacy trials have been completed for any clinical endpoint. The compound's development was discontinued, and its use outside of formal clinical research represents unapproved human experimentation.

This article is intended for educational and research purposes only and does not constitute medical advice. Exogenous manipulation of the GH/IGF-1 axis carries meaningful risks including but not limited to insulin resistance, fluid retention, potential cancer risk promotion, and pituitary axis dysregulation. These risks are not trivial and should not be minimized by the availability of the compound as a research peptide.

The evidence grade of B assigned on this platform reflects the existence of Phase I human data and a mechanistically coherent basis for the compound's effects — not equivalence to a fully clinically validated therapeutic.

Community Research Notes

I ran CJC-1295 with DAC at 1 mg twice weekly alongside Ipamorelin at 200 mcg three times daily for 16 weeks. The first noticeable change was sleep — deeper and more consolidating within about ten days. By week six I had measurably reduced body fat on a DEXA scan and my gym recovery between sessions was significantly faster. The combination feels qualitatively different from either compound alone; the GH pulse from Ipamorelin on top of the sustained CJC baseline is noticeably stronger.

— Research participant, 34M, tracking via DEXA and IGF-1 bloodwork

Twelve weeks in on Mod GRF 1-29 100 mcg plus Ipamorelin 200 mcg at bedtime only. I lost approximately 4 kg of fat while gaining roughly 1.5 kg of lean mass according to InBody scans. Skin texture improved noticeably — less dry, more elastic. The changes were gradual and linear across the three months, not dramatic early and flat later. I'd characterise this as a slow recomposition rather than anything acute.

— Research participant, 41F, 12-week log

Sleep quality was my primary motivation and it exceeded expectations. Within two weeks on the CJC/Ipamorelin protocol I was hitting deeper slow-wave phases on my Oura ring than I had in years. Muscle soreness after training sessions was reduced by what felt like 30–40%. I was training six days a week during this period and the recovery gap between sessions shrank considerably. My mood was notably more stable — I attribute this to better sleep compounding over weeks.

— Research participant, 38M, sleep and HRV tracking

I ran the no-DAC form (Mod GRF 1-29) for eight weeks, then switched to CJC-1295 with DAC for eight weeks to compare. The no-DAC form gave me pronounced GH pulses I could feel — a warmth and heaviness at night, clear sleep intensification. The DAC form was quieter day-to-day but I noticed steadier body composition changes and less fluctuation. Bloodwork showed IGF-1 considerably more elevated on DAC. If pulsatility matters to you the no-DAC form is more experiential; if you want sustained IGF-1 elevation and once-weekly dosing convenience, DAC is easier to manage.

— Research participant, 29M, comparative 16-week log

Frequently Asked Questions

What is the difference between CJC-1295 with DAC and without DAC (Mod GRF 1-29)?

Both compounds activate the same GHRH receptor on pituitary somatotroph cells, but their pharmacokinetics are fundamentally different. CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF 1-29) has a plasma half-life of approximately 30 minutes. It produces a short, defined GH pulse when injected and is therefore timed carefully — typically pre-sleep or pre-training in a fasted state — to coincide with low somatostatin tone. CJC-1295 with DAC carries a maleimide-reactive group that binds covalently to albumin shortly after injection, extending the effective half-life to 6–8 days. This transforms it from a pulse-augmenting tool to a continuous baseline GHRH agonist. The DAC form is typically dosed once or twice weekly and produces steadier, sustained GH and IGF-1 elevation rather than defined pulses. The DAC form blunts the natural pulsatile architecture of GH secretion; whether this matters for long-term outcomes is unknown. For pulse preservation and combination with GHRPs, the no-DAC form is generally preferred. For convenience and sustained IGF-1 elevation, the DAC form is more practical.

Why is CJC-1295 almost always combined with Ipamorelin?

CJC-1295 acts at the GHRH receptor (GHRHR) while Ipamorelin acts at the ghrelin/GH secretagogue receptor (GHS-R1a). These are distinct receptor systems on pituitary somatotrophs, and their activation is synergistic rather than additive. GHRHR activation increases cAMP and primes the somatotroph for GH secretion; GHS-R1a activation through a separate Gq/phospholipase C pathway amplifies the GH release response. Studies of GHRH plus GHRP co-administration in humans and animals consistently show GH release substantially greater than either agent alone. Ipamorelin is the preferred GHRP partner because it has a relatively clean profile — it produces less cortisol and prolactin elevation than older GHRPs such as GHRP-6 or hexarelin, making the combination more tolerable and the hormonal effects more targeted.

What results can be expected from a 12-week cycle?

Based on the mechanistic effects of GH and IGF-1 elevation and consistent with what is reported in research community logs, a 12-week CJC-1295 / Ipamorelin cycle is typically associated with: gradual improvement in body composition (modest fat reduction, modest lean mass increase), improved sleep quality and depth, faster recovery between training sessions, and improvements in skin texture and thickness. These changes are generally gradual — appearing over weeks rather than days — and are not of the magnitude associated with anabolic steroids. IGF-1 bloodwork typically shows elevation within the upper physiological range. The Phase I clinical data confirms that GH and IGF-1 elevation at community-level doses is pharmacologically real; the body composition and performance effects in humans are inferred from mechanism rather than established by controlled trials.

Should CJC-1295 be taken on an empty stomach?

For the non-DAC form (Mod GRF 1-29), fasting state at injection time is meaningful. Elevated insulin — as occurs after a meal — suppresses GH release through somatostatin pathways, which would attenuate the GH pulse produced by the injection. Injecting in a fasted state (typically 2+ hours post-meal) allows a cleaner, higher-amplitude GH pulse. For CJC-1295 with DAC, where the pharmacological effect is a sustained multi-day GH elevation rather than a defined pulse, the timing relative to food is less critical and fasting is not required. The general guidance of avoiding a large carbohydrate or insulin-spiking meal within two hours of injection is a reasonable precaution for either form.

What is the ideal timing — morning or bedtime?

For the non-DAC form, bedtime injection is generally considered optimal. The largest natural GH pulse occurs in early slow-wave sleep, and administering a GHRH analogue shortly before sleep augments this existing pulse when somatostatin tone is at its lowest. This also means the GH effects coincide with the period of natural GH secretion, preserving pulsatile dynamics. Pre-training administration in a fasted state is a secondary approach used for potential performance and fat metabolism effects. For CJC-1295 with DAC, timing has minimal impact given the multi-day duration of action. Bedtime is still commonly preferred for practical reasons and to combine with GHRP injections, but morning dosing is equally valid.

Can CJC-1295 be used alongside MK-677?

MK-677 (ibutamoren) is an orally bioavailable, non-peptide GHS-R1a agonist — the same receptor class as Ipamorelin but taken orally. Combining CJC-1295 with MK-677 would therefore be mechanistically analogous to combining CJC-1295 with a GHRP, acting on complementary receptor systems. The oral convenience of MK-677 makes this combination appealing for those who prefer to minimise injections. Key considerations: MK-677's longer half-life (6 hours) and oral route produce a more sustained GHS-R1a stimulation than injectable GHRPs, which may produce more water retention and cortisol elevation. The combination will produce substantially elevated IGF-1, which should be monitored via bloodwork if used for extended periods. No formal safety or efficacy data exists for this specific combination in humans.

Compounds That Pair Well

Ipamorelin

The primary and most studied combination partner for CJC-1295. Ipamorelin activates GHS-R1a while CJC-1295 activates GHRHR, producing synergistic GH release through two complementary pituitary receptor systems. The combination is mechanistically well-supported and is the most common stack in the GH-axis peptide research community. Ipamorelin's relatively clean side-effect profile — modest prolactin and cortisol impact compared to older GHRPs — makes it the preferred choice for this pairing.

BPC-157

Frequently added to CJC-1295 / Ipamorelin stacks as a recovery and tissue repair complement. BPC-157 operates through nitric oxide-dependent and growth factor receptor-dependent wound healing pathways entirely distinct from the GH axis. The combination is used in injury recovery contexts where CJC-1295 provides systemic GH/IGF-1 support for anabolism and healing while BPC-157 addresses local tissue repair, inflammation, and gut health. No formal interaction or combination trial exists.

MK-677

An oral GHS-R1a agonist that can substitute for or supplement injectable GHRPs in a GH-axis stack. Combining MK-677 with CJC-1295 with DAC produces sustained, multi-modal GH axis stimulation from two different receptor systems, both via non-pulsatile, long-acting mechanisms. This combination has appeal for convenience but carries higher risk of sustained IGF-1 elevation and associated side effects. IGF-1 monitoring is advisable.

Tesamorelin

Tesamorelin is an FDA-approved GHRH analogue (approved for HIV-associated lipodystrophy) structurally related to CJC-1295 without DAC. It consists of GHRH[1-44] with a trans-3-hexenoic acid modification at the N-terminus conferring DPP-IV resistance. Tesamorelin has a substantially larger evidence base than CJC-1295, including controlled efficacy trials demonstrating visceral fat reduction. Researchers comparing GHRH analogues should note that tesamorelin has demonstrated human efficacy for body composition while CJC-1295's body composition effects remain inferred from mechanism rather than confirmed in trials.

Sermorelin

Sermorelin is a synthetic GHRH[1-29] analogue and the oldest clinically used GHRH analogue, formerly FDA-approved for paediatric GH deficiency diagnosis and treatment. It is pharmacologically very similar to Mod GRF 1-29 (CJC-1295 without DAC) but lacks the amino acid substitutions that confer DPP-IV resistance, resulting in a shorter half-life of approximately 11 minutes. Researchers considering Mod GRF 1-29 may find sermorelin's clinical trial data — which includes studies in adult GH deficiency and aging — informative for understanding what the class can achieve in humans with more extended data.

Build Your Personalised Protocol

CJC-1295 is one of many compounds available in the BioStack Generator. Often studied in combination with Ipamorelin for synergistic GH release.

Get Your BioStack →